STOCK TITAN

Psyence Biomedical’s operating cash use falls to $395K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Psyence Biomedical Ltd. (PBM) reported a net loss of $1,937,058 for the six months ended September 30, 2026, versus $1,992,732 in the six months ended September 30, 2025. Operating cash used fell to $394,565 from $2,029,147; PBM attributed reduced outflows to $897,751 in prepaid amounts realized and $424,695 in insurance recoveries. Cash and cash equivalents, including restricted cash, were $21,140,337 at September 30, 2026, versus $7,491,954 at March 31, 2026. Research and development expense was $890,254, chiefly for its Australian Phase IIb study, where multiple patients had been enrolled and dosed.

On October 1, 2026, PBM issued 1,497,500 common shares at a deemed $6.00 per share for 3,473 PsyLabs shares; on October 16, 2026, it subscribed for 1,014 more at $2,564 per share for $2,599,896, bringing its PsyLabs holding to 11,565 shares, approximately 43.37%. Net ELOC proceeds were $16,780,447 for the six months. The ELOC permits sales of up to $100 million in shares through December 31, 2027, subject to agreement conditions, with $61,836,722 available as of November 19, 2026. Psyence Australia received an AUD $1,034,681 ($710,363) research-and-development rebate on November 10, 2026.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointOperating cash used fell to $394,565 from $2,029,147.

Negative

  • None.

Filing Explained

After the completed October share swap and subsequent issuances, Psyence Biomedical reported November 19, 2026 common shares outstanding of 5,318,218, up from 3,816,548 on September 30, 2026; the higher share count reduces existing holders’ percentage ownership absent offsetting changes.

Net loss $1,937,058 Six months ended September 30, 2026; $1,992,732 in the six months ended September 30, 2025.
Cash used in operating activities $394,565 Six months ended September 30, 2026; $2,029,147 in the six months ended September 30, 2025.
Cash and cash equivalents, including restricted cash $21,140,337 As of September 30, 2026; $7,491,954 as of March 31, 2026.
Research and development expense $890,254 Six months ended September 30, 2026; $672,364 in the six months ended September 30, 2025.
Net ELOC proceeds $16,780,447 Six months ended September 30, 2026.
Common shares issued in PsyLabs share-for-share swap 1,497,500 shares Issued October 1, 2026, at a deemed issue price of $6.00 per share.
PsyLabs ownership Approximately 43.37% PBM held 11,565 PsyLabs shares following the October 2026 transactions.
Research and development tax incentive rebate $710,363 Received by Psyence Australia on November 10, 2026; equivalent to AUD $1,034,681.
equity line of credit financial
"entered into a $25 million equity line of credit agreement"
An equity line of credit is a loan that allows homeowners to borrow money against the value of their property, similar to having a flexible credit card secured by their home. It matters to investors because it provides a way for property owners to access cash for various needs, which can influence real estate markets and overall economic activity. This type of credit offers ongoing borrowing capacity, making it a valuable financial tool for those with significant property equity.
equity method financial
"accounted for as an associate using the equity method"
An equity method investment is an accounting approach used when a company owns enough of another business to influence its decisions but not control it (commonly around 20–50% ownership). Instead of counting only dividends, the investor records its share of the other company’s profits and losses on its own income statement and adjusts the investment’s value on the balance sheet—like tracking a friend’s joint project by noting your share of their gains or setbacks. For investors, this matters because it can significantly affect reported earnings, asset values, and the apparent strength of a company’s financial results.
Phase IIb Study medical
"Phase IIb Study to assess the efficacy and safety"
cGMP ibogaine HCl technical
"related intellectual property for its cGMP ibogaine HCl"
restricted stock units financial
"restricted stock units granted by the Company"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
revaluation model financial
"accounted for as an intangible asset using the revaluation model"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was PBM’s net loss for the six months ended September 30, 2026?

PBM reported a net loss of $1,937,058 for the six months ended September 30, 2026, compared with $1,992,732 in the same period of 2025.

How much cash did PBM have at September 30, 2026?

Cash and cash equivalents, including restricted cash, were $21,140,337 at September 30, 2026; the March 31, 2026 balance was $7,491,954.

How many patients is PBM’s Phase IIb study designed to include?

The Australian Phase IIb study is an 87-patient study conducted by Southern Star Research. It has ethics approval, and multiple patients have been enrolled and dosed.

What are PBM’s terms with PsyLabs for U.S. ibogaine?

On September 25, 2026, Texas Ibogaine Research Corporation and PsyLabs entered a binding term sheet. PsyLabs will grant an exclusive U.S. license to its know-how and related intellectual property for cGMP ibogaine HCl and appoint the subsidiary exclusive supplier and wholesale distributor. Terms include development milestone payments totaling up to approximately US$1.3 million for the first drug candidate, an annual exclusivity fee beginning on the first anniversary of the first FDA approval and creditable against royalties, a low single-digit percentage royalty on net sales, and margin sharing on resales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001985062 Q2 false --03-31 2026-09-30 2027 0001985062 2026-04-01 2026-09-30 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember ifrs-full:BottomOfRangeMember 2026-11-10 2026-11-10 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember ifrs-full:TopOfRangeMember 2026-11-10 2026-11-10 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember 2026-04-01 2026-09-30 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember 2026-09-30 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember ifrs-full:TopOfRangeMember 2026-09-30 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember ifrs-full:BottomOfRangeMember 2026-09-30 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember 2026-09-16 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:SecondPsyLabsMember 2026-10-16 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:SecondPsyLabsMember 2026-10-16 2026-10-16 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember 2026-10-01 2026-10-01 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyenceBiomedIICorpMember 2026-10-01 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:PsyLabsMember 2026-10-01 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember ifrs-full:RestrictedShareUnitsMember 2026-10-12 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:ELOCMember 2026-09-30 0001985062 ifrs-full:MajorOrdinaryShareTransactionsMember pbm:ELOCMember 2026-04-01 2026-09-30 0001985062 2025-04-01 2025-09-30 0001985062 2026-09-30 0001985062 ifrs-full:NotLaterThanOneYearMember 2026-09-30 0001985062 ifrs-full:NotLaterThanOneYearMember pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember 2026-09-30 0001985062 pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember 2026-09-30 0001985062 2026-03-31 0001985062 ifrs-full:Level1OfFairValueHierarchyMember 2026-03-31 0001985062 pbm:WarrantLiabilitiesMember pbm:PublicWarrantsMember 2026-03-31 0001985062 pbm:WarrantLiabilitiesMember ifrs-full:Level1OfFairValueHierarchyMember pbm:PublicWarrantsMember 2026-03-31 0001985062 ifrs-full:Level1OfFairValueHierarchyMember 2026-09-30 0001985062 pbm:WarrantLiabilitiesMember pbm:PublicWarrantsMember 2026-09-30 0001985062 pbm:WarrantLiabilitiesMember ifrs-full:Level1OfFairValueHierarchyMember pbm:PublicWarrantsMember 2026-09-30 0001985062 2026-09-25 0001985062 pbm:PsyLabsShareholdersMember 2026-09-30 0001985062 2026-07-01 2026-09-30 0001985062 pbm:PsyenceLabsLtdMember 2026-09-30 0001985062 pbm:PsyLabsMember 2026-04-01 2026-09-30 0001985062 pbm:PsyLabsMember 2026-09-16 0001985062 pbm:PsyLabsMember 2026-09-09 0001985062 2026-08-31 0001985062 pbm:PsyenceLabsLtdMember 2026-08-31 0001985062 ifrs-full:TopOfRangeMember 2026-02-25 2026-02-25 0001985062 ifrs-full:BottomOfRangeMember 2026-02-25 2026-02-25 0001985062 pbm:RestrictedStockUnitsRSUsMember 2026-04-01 2026-09-30 0001985062 pbm:ForecastMember 2027-12-01 0001985062 pbm:ForecastMember 2027-06-01 0001985062 pbm:ForecastMember 2026-12-01 0001985062 pbm:RestrictedStockUnitsRSUsMember 2026-06-01 0001985062 ifrs-full:RestrictedShareUnitsMember 2025-09-30 0001985062 ifrs-full:RestrictedShareUnitsMember 2026-09-30 0001985062 ifrs-full:RestrictedShareUnitsMember 2026-04-01 2026-09-30 0001985062 ifrs-full:RestrictedShareUnitsMember 2025-04-01 2025-09-30 0001985062 ifrs-full:RestrictedShareUnitsMember 2026-03-31 0001985062 pbm:DecemberTwentyFourTwoMember 2026-09-30 0001985062 pbm:DecemberTwentyFourOneMember 2026-09-30 0001985062 pbm:DecemberTwenteyFourMember 2026-09-30 0001985062 2026-08-20 2026-08-20 0001985062 2026-08-20 0001985062 ifrs-full:WarrantsMember 2026-03-31 0001985062 ifrs-full:WarrantsMember 2026-09-30 0001985062 ifrs-full:OrdinarySharesMember pbm:PGIMember 2025-05-31 0001985062 pbm:IssuedCapital1Member 2025-09-30 0001985062 pbm:IssuedCapital1Member 2026-09-30 0001985062 pbm:IssuedCapital1Member 2025-04-01 2025-09-30 0001985062 pbm:IssuedCapital1Member 2026-04-01 2026-09-30 0001985062 pbm:IssuedCapital1Member 2025-03-31 0001985062 pbm:IssuedCapital1Member 2026-03-31 0001985062 ifrs-full:OrdinarySharesMember 2025-09-30 0001985062 ifrs-full:OrdinarySharesMember 2026-09-30 0001985062 2026-02-02 2026-02-02 0001985062 2025-05-05 2025-05-05 0001985062 2024-11-26 2024-11-26 0001985062 pbm:ELOCMember 2025-04-01 2025-09-30 0001985062 pbm:ELOCMember 2026-04-01 2026-09-30 0001985062 pbm:ELOCMember ifrs-full:OrdinarySharesMember 2025-09-30 0001985062 pbm:ELOCMember ifrs-full:OrdinarySharesMember 2026-09-30 0001985062 pbm:ELOCMember 2024-08-28 2024-08-28 0001985062 pbm:WhiteLionCapitalLLCMember 2024-08-28 2024-08-28 0001985062 pbm:CuriosumLtdMember 2026-04-01 2026-09-30 0001985062 2026-05-19 2026-05-19 0001985062 ifrs-full:TopOfRangeMember 2026-03-31 0001985062 ifrs-full:BottomOfRangeMember 2026-03-31 2026-03-31 0001985062 2026-02-09 0001985062 ifrs-full:WarrantsMember 2026-09-30 0001985062 ifrs-full:WarrantsMember 2026-04-01 2026-09-30 0001985062 pbm:PrivateWarrantsMember 2026-09-30 0001985062 pbm:PublicWarrantsMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember 2025-09-30 0001985062 pbm:PublicWarrantsMember 2025-09-30 0001985062 pbm:PrivateWarrantsMember 2025-03-31 0001985062 pbm:PublicWarrantsMember 2025-03-31 0001985062 2025-09-30 0001985062 2025-03-31 0001985062 pbm:PublicWarrantsMember 2026-03-31 0001985062 pbm:DerivativeWarrantLiabilitiesMember pbm:PublicWarrantsMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember pbm:ExpiryDateMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember pbm:ExpiryDateMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember pbm:ExpectedLifeMeasurementInputMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember pbm:ExpectedLifeMeasurementInputMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember ifrs-full:InterestRateMeasurementInputMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember ifrs-full:InterestRateMeasurementInputMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember pbm:ExercisePriceMeasurementInputMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember pbm:ExercisePriceMeasurementInputMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember pbm:SharePriceMeasurementInputMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember pbm:SharePriceMeasurementInputMember 2026-09-30 0001985062 pbm:DerivativeWarrantLiabilitiesMember pbm:PrivateWarrantsMember 2026-09-30 0001985062 pbm:DerivativeWarrantLiabilitiesMember 2026-03-31 0001985062 pbm:DerivativeWarrantLiabilitiesMember 2026-09-30 0001985062 2026-03-31 2026-03-31 0001985062 pbm:CashAssetMember 2026-03-31 2026-03-31 0001985062 pbm:CashAssetMember 2026-04-01 2026-09-30 0001985062 pbm:CashAssetMember 2026-09-30 0001985062 pbm:USDCoinMember 2026-03-31 2026-03-31 0001985062 pbm:USDCoinMember 2026-04-01 2026-09-30 0001985062 pbm:USDCoinMember 2026-09-30 0001985062 pbm:TetherMember 2026-03-31 2026-03-31 0001985062 pbm:TetherMember 2026-04-01 2026-09-30 0001985062 pbm:TetherMember 2026-09-30 0001985062 pbm:SolanaMember 2026-04-01 2026-09-30 0001985062 pbm:SolanaMember 2026-03-31 2026-03-31 0001985062 pbm:SolanaMember 2026-09-30 0001985062 pbm:EthereumMember 2026-04-01 2026-09-30 0001985062 pbm:EthereumMember 2026-03-31 2026-03-31 0001985062 pbm:EthereumMember 2026-09-30 0001985062 pbm:BitcoinMember 2026-04-01 2026-09-30 0001985062 pbm:BitcoinMember 2026-03-31 2026-03-31 0001985062 pbm:BitcoinMember 2026-09-30 0001985062 2025-04-01 2026-03-31 0001985062 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerEquipmentMember 2026-09-30 0001985062 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerEquipmentMember 2026-04-01 2026-09-30 0001985062 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerEquipmentMember 2026-03-31 0001985062 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerEquipmentMember 2025-09-30 0001985062 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerEquipmentMember 2025-04-01 2025-09-30 0001985062 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerEquipmentMember 2025-03-31 0001985062 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerEquipmentMember 2026-09-30 0001985062 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerEquipmentMember 2026-04-01 2026-09-30 0001985062 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerEquipmentMember 2026-03-31 0001985062 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerEquipmentMember 2025-09-30 0001985062 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerEquipmentMember 2025-04-01 2025-09-30 0001985062 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerEquipmentMember 2025-03-31 0001985062 pbm:TexasIbogaineResearchCorporationMember 2026-04-01 2026-09-30 0001985062 pbm:NewcourtAcquisitionCorpMember 2026-04-01 2026-09-30 0001985062 pbm:PysenceBiomedIICorpMember 2026-04-01 2026-09-30 0001985062 pbm:PsyenceAustraliaPtyLtdMember 2026-04-01 2026-09-30 0001985062 ifrs-full:RetainedEarningsMember 2026-09-30 0001985062 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2026-09-30 0001985062 pbm:OptionsReserveMember 2026-09-30 0001985062 pbm:WarrantsReserveMember 2026-09-30 0001985062 ifrs-full:IssuedCapitalMember 2026-09-30 0001985062 ifrs-full:OrdinarySharesMember 2026-09-30 0001985062 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2026-04-01 2026-09-30 0001985062 ifrs-full:RetainedEarningsMember 2026-04-01 2026-09-30 0001985062 pbm:OptionsReserveMember 2026-04-01 2026-09-30 0001985062 ifrs-full:IssuedCapitalMember 2026-04-01 2026-09-30 0001985062 ifrs-full:OrdinarySharesMember 2026-04-01 2026-09-30 0001985062 ifrs-full:RetainedEarningsMember 2026-03-31 0001985062 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2026-03-31 0001985062 pbm:OptionsReserveMember 2026-03-31 0001985062 pbm:WarrantsReserveMember 2026-03-31 0001985062 ifrs-full:IssuedCapitalMember 2026-03-31 0001985062 ifrs-full:OrdinarySharesMember 2026-03-31 0001985062 ifrs-full:RetainedEarningsMember 2025-09-30 0001985062 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-09-30 0001985062 pbm:OptionsReserveMember 2025-09-30 0001985062 pbm:WarrantsReserveMember 2025-09-30 0001985062 ifrs-full:IssuedCapitalMember 2025-09-30 0001985062 ifrs-full:OrdinarySharesMember 2025-09-30 0001985062 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-04-01 2025-09-30 0001985062 ifrs-full:RetainedEarningsMember 2025-04-01 2025-09-30 0001985062 pbm:OptionsReserveMember 2025-04-01 2025-09-30 0001985062 ifrs-full:IssuedCapitalMember 2025-04-01 2025-09-30 0001985062 ifrs-full:OrdinarySharesMember 2025-04-01 2025-09-30 0001985062 ifrs-full:RetainedEarningsMember 2025-03-31 0001985062 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-03-31 0001985062 pbm:WarrantsReserveMember 2025-03-31 0001985062 ifrs-full:IssuedCapitalMember 2025-03-31 0001985062 ifrs-full:OrdinarySharesMember 2025-03-31 0001985062 2025-07-01 2025-09-30 0001985062 pbm:WarrantsReserveMember 2026-04-01 2026-09-30 0001985062 pbm:OptionsReserveMember 2025-03-31 0001985062 ifrs-full:Level2OfFairValueHierarchyMember 2026-03-31 0001985062 ifrs-full:Level3OfFairValueHierarchyMember 2026-03-31 0001985062 ifrs-full:RestrictedShareUnitsMember 2025-03-31 0001985062 pbm:WarrantsReserveMember 2025-04-01 2025-09-30 0001985062 pbm:PrivateWarrantsMember pbm:ExpectedDividendYieldMeasurementInputMember 2026-09-30 0001985062 pbm:PrivateWarrantsMember pbm:ExpectedDividendYieldMeasurementInputMember 2026-03-31 0001985062 pbm:PrivateWarrantsMember 2026-03-31 0001985062 ifrs-full:Level2OfFairValueHierarchyMember 2026-09-30 0001985062 ifrs-full:Level3OfFairValueHierarchyMember 2026-09-30 0001985062 pbm:WarrantLiabilitiesMember ifrs-full:Level2OfFairValueHierarchyMember pbm:PublicWarrantsMember 2026-03-31 0001985062 pbm:WarrantLiabilitiesMember ifrs-full:Level3OfFairValueHierarchyMember pbm:PublicWarrantsMember 2026-03-31 0001985062 pbm:WarrantLiabilitiesMember ifrs-full:Level2OfFairValueHierarchyMember pbm:PublicWarrantsMember 2026-09-30 0001985062 pbm:WarrantLiabilitiesMember ifrs-full:Level3OfFairValueHierarchyMember pbm:PublicWarrantsMember 2026-09-30 0001985062 ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember 2026-09-30 0001985062 ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2026-09-30 iso4217:AUD xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:CAD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-41937

 

Psyence Biomedical Ltd.

(Translation of registrant’s name into English)

 

121 Richmond Street West

Penthouse Suite 1300

Toronto, Ontario M5H 2K1

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

☒ Form 20-F       ☐ Form 40-F

 

 

 

 

EXPLANATORY NOTE

 

Psyence Biomedical Ltd. (the “Company”) is filing this Form 6-K to file its unaudited condensed consolidated interim financial statements for the three and six months ended September 30, 2026 and 2025 (the “Interim Financial Statements”), attached hereto as Exhibit 99.1, along with its corresponding Management Discussion and Analysis, attached hereto as Exhibit 99.2.

 

1

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Unaudited Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended September 30, 2026 and 2025.
99.2   Management Discussion and Analysis for the Unaudited Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended September 30, 2026 and 2025.
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: November 19, 2026

 

  Psyence Biomedical Ltd.
     
  By: /s/ Jody Aufrichtig
  Name:  Jody Aufrichtig
  Title: Chief Executive Officer and Director

 

3

 

Exhibit 99.1

 

 

Psyence Biomedical Ltd.

 

Unaudited Condensed Consolidated Interim Financial Statements

 

For the three and six months ended September 30, 2026 and 2025

 

Expressed in United States Dollars

 

(USD $)

 

 

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Condensed Consolidated Interim Statements of Financial Position

 

As at September 30, 2026 and March 31, 2026

 

USD $   Note    

As at
September 30,
2026

(Unaudited)

   

As at

March 31,

2026

(Audited)

 
                   
ASSETS                  
Current assets                  
Cash and cash equivalents     5       21,068,527       7,444,763  
Restricted cash     5       71,810       47,191  
Other receivables             57,738       109,779  
Loan receivable     10       -       252,985  
Prepaids             358,106       1,255,857  
Total current assets             21,556,181       9,110,575  
Non-current assets                        
Digital assets     8       495,646       389,758  
Equipment     6       5,838       6,059  
Investment in Associate     13       10,740,433       8,060,928  
TOTAL ASSETS             32,798,098       17,567,320  
LIABILITIES                        
Current liabilities                        
Accounts payable and accrued liabilities     7       469,862       407,714  
Derivative warrant liabilities     9       248,640       215,476  
TOTAL LIABILITIES             718,502       623,190  
SHAREHOLDERS EQUITY                        
Share Capital     12       95,605,014       78,747,983  
Accumulated Deficit             (65,320,683 )     (63,383,625 )
Warrant Reserve             1,065,705       1,065,705  
Options Reserve     12       329,043       117,890  
Reserves             400,517       396,177  
TOTAL SHAREHOLDERS EQUITY             32,079,596       16,944,130  
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY             32,798,098       17,567,320  

 

Approved on behalf of Board of Directors

 

“Jody Aufrichtig”   “Warwick Corden-Lloyd”
Chief Executive Officer and Director   Chief Financial Officer and Director

 

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

 

 

2

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss

 

For three and six months ended September 30, 2026 and 2025

 

USD $   Note     Three months ending
September 30,
2026
    Three months ending
September 30,
2025
    Six months ending
September 30,
2026
    Six months ending
September 30,
2025
 
Expenses                              
Sales and marketing             105,506       48,670       119,646       154,976  
Research and development             527,967       357,444       890,254       672,364  
General and administrative     16       173,282       217,225       320,000       367,070  
Professional and consulting fees     16       782,312       881,638       1,151,393       1,223,637  
Loss before other items             (1,589,067 )     (1,504,977 )     (2,481,293 )     (2,418,047 )
Other items                                        
Depreciation     6       (1,486 )     (1,330 )     (2,802 )     (2,634 )
Interest expense             (2,482 )     (2,753 )     (5,075 )     (5,125 )
Interest income             224,287       72,815       362,187       103,341  
Other income     18       424,695       -       424,695       2,533  
Foreign exchange (loss)/gain             (2,531 )     257       (971 )     (1,528 )
Fair value gain/(loss) on warrant liability     9       39,072       (58,016 )     (33,164 )     (98,272 )
Fair value gain on investment in Psyence Labs Ltd     13       -       740,750       -       427,000  
Fair value gain on digital assets     8       165,868       -       105,888       -  
Share of losses from Associate     13       (171,261 )     -       (306,523 )     -  
NET LOSS             (912,905 )     (753,254 )     (1,937,058 )     (1,992,732 )
Other comprehensive income/(loss)                                        
Foreign exchange (loss)/gain on translation             (8,471 )     636       4,340       (3,945 )
TOTAL COMPREHENSIVE LOSS             (921,376 )     (752,618 )     (1,932,718 )     (1,996,677 )
Profit/(Loss) per share – basic & diluted             (0.24 )     (3.18 )     (0.53 )     (11.76 )
Weighted average number of outstanding shares – basic & diluted             3,814,673       237,044       3,668,962       169,506  

 

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

 

 

3

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Condensed Consolidated Interim Statements of Changes in Shareholder Equity

 

For the six months ended September 30, 2026 and 2025

 

USD $   Note     Number of
shares
    Share capital     Warrant
reserve
    Options
Reserve
    Reserves     Accumulated
Deficit
    Total
shareholders’
equity
 
Opening balance as at April 1, 2025             90,883       61,752,305       1,065,705       -       351,198       (56,447,204 )     6,722,004  
Issuance of shares to third party advisors     12       2,439       60,000       -       -       -       -       60,000  
Issuance of shares for ELOC, net of issuance costs     11/12     205,432       7,055,421       -       -       -       -       7,055,421  
Share based compensation     16       -       -       -       26,329       -       -       26,329  
Exercise of RSU’s     12       774       16,884       -       (16,884 )     -       -       -  
Net loss for the period             -       -       -       -       -       (1,992,732 )     (1,992,732 )
Other comprehensive loss             -       -       -       -       (3,945 )     -       (3,945 )
Balance, September 30, 2025             299,528       68,884,610       1,065,705       9,445       347,253       (58,439,936 )     11,867,077  
                                                                 
Opening balance as at April 1, 2026             2,293,277       78,747,983       1,065,705       117,890       396,177       (63,383,625 )     16,944,130  
Issuance of shares for ELOC, net of issuance costs     11/12       1,519,383       16,780,447       -       -       -       -       16,780,447  
Share based compensation     16       -       -       -       287,737       -       -       287,737  
Exercise of RSU’s     12       3,888       76,584       -       (76,584 )     -       -       -  
Net loss for the period             -       -       -       -       -       (1,937,058 )     (1,937,058 )
Other comprehensive income             -       -       -       -       4,340       -       4,340  
Balance, September 30, 2026             3,816,548       95,605,014       1,065,705       329,043       400,517       (65,320,683 )     32,079,596  

 

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

 

 

4

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Condensed Consolidated Interim Statements of Cash Flows

 

For the six months ended September 30, 2026 and September 30, 2025

 

    Note     Six months ending
September 30,
2026
    Six months ending
September 30,
2025
 
                   
                   
Net (loss)/ income             (1,937,058 )     (1,992,732 )
Non-cash adjustment:                        
Fair value loss on derivative warrant     9       33,164       98,272  
Fair value gain on investment in Psyence Labs Ltd     13       -       (427,000 )
Fair value gain on digital assets     8       (105,888 )     -  
Share of losses from Associate     13       306,523       -  
Third party advisors share issuance     12       -       60,000  
Share based compensation     16       287,737       26,329  
Depreciation     6       2,802       2,634  
Foreign exchange             4,340       (3,945 )
                         
Changes in working capital:                        
Other receivables             52,041       (36,839 )
Loan receivable     10       1,875       -  
Prepaids             897,751       (6,296 )
Accounts payable and accrued liabilities     7       62,148       250,430  
Cash used in operating activities             (394,565 )     (2,029,147 )
                         
Additions to equipment     6       (2,581 )     (228 )
Investment in Psyence Labs     13       (2,986,028 )     (4,000,000 )
Increase in restricted cash     5       (24,619 )     (11,227 )
Repayment of loan receivable     10       251,110       -  
Cash used for investing activities             (2,762,118 )     (4,011,455 )
                         
Net proceeds received from ELOC     11       16,780,447       7,055,421  
Cash provided from financing activities             16,780,447       7,055,421  
                         
Change in cash and cash equivalents             13,623,764       1,014,819  
Cash and cash equivalents, beginning of period             7,444,763       6,135,166  
Cash and cash equivalents, end of period             21,068,527       7,149,985  

 

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

 

 

5

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Notes to the Condensed Consolidated Interim Financial Statements

 

1. Nature of operations

 

Psyence Biomedical Ltd. (the “Company” or “PBM”), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin and ibogaine-based neuroplastogen medicines. The Company is working towards developing psychedelic therapeutics to treat mental health disorders. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative care context (the “Clinical Trials”).

 

The Company’s registered office is at 121 Richmond Street West, PH Suite 1300, Toronto, Ontario M5H 2K1.

 

On November 26, 2024, the Company consolidated its common shares and warrants on the basis of 75:1.

 

On May 5, 2025, the Company consolidated its common shares and warrants on the basis of 7.97:1.

 

On February 2, 2026, the Company consolidated its common shares and warrants on the basis of 6.25:1.

 

All prior share capital information, including comparative figures, has been presented based on these ratios.

 

2. Basis of presentation

 

Statement of compliance

 

These Condensed Consolidated Interim Financial Statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). Accordingly, certain disclosures included in annual consolidated financial statements prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standards Board (“IFRS”) have been condensed or omitted and these Unaudited Condensed Consolidated Interim Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements for the year ended March 31, 2026 and March 31, 2025. These Unaudited Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent annual consolidated financial statements.

 

The Condensed Consolidated Interim Financial Statements were authorized for issue on November 19, 2026 by the directors of the Company.

 

Basis of consolidation

 

These Condensed Consolidated Interim Financial Statements incorporate the accounts of PBM and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.

 

Control exists when an investor is exposed, or has the rights, to variable returns from the involvement with the investee and has the ability to affect those returns through its power over the investee.

 

The subsidiaries of PBM as at September 30, 2026 for the purpose of these Condensed Consolidated Interim Financial Statements are as follows:

 

Name of entity   Place of incorporation   % ownership     Accounting method
Psyence Australia Pty Ltd.   Australia     100 %   Consolidated
Psyence Biomed II Corp.   Canada     100 %   Consolidated
Newcourt Acquisition Corp.   Cayman Islands     100 %   Consolidated
Texas Ibogaine Research Corporation   United States     100 %   Consolidated

 

 

6

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Inter-company balances and transactions are eliminated upon consolidation.

 

Texas Ibogaine Research Corporation (“TIRC”) was incorporated in the State of Texas on September 8, 2026 as a wholly owned subsidiary of Psyence Biomed II Corp.

 

Functional and presentation currency

 

These Condensed Consolidated Interim Financial Statements are presented in United States Dollars (“USD $”), which is also PBM’s functional currency. The USD $ represents the currency of the Company’s funding and is the currency of the primary economic environment in which the Company operates in, except for the Company’s Australian subsidiary which has an Australian Dollar functional currency.

 

3. Material accounting policies

 

These Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent Annual audited Consolidated Financial Statements.

 

Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7) became effective for annual reporting periods beginning on or after January 1, 2026 and were adopted by the Company on April 1, 2026. The adoption of these amendments did not have a material impact on these Condensed Consolidated Interim Financial Statements.

 

Accounting Standards Issued But Not Yet Effective

 

A number of new standards, and amendments to standards and interpretations, are not yet effective for the period ended September 30, 2026, and have not been early adopted in preparing these consolidated financial statements.

 

IFRS 18 Presentation and Disclosure in Financial Statements

 

In April 2024, the IASB issued IFRS 18 – Presentation and Disclosure in Financial Statements which will replace IAS 1, Presentation of Financial Statements. The key new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the process of assessing the impact of this standard on its consolidated financial statements.

 

Other accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are not expected to have a significant impact on the Company’s consolidated financial statements.

 

4. Critical accounting estimates and judgements

 

These Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent Annual audited Consolidated Financial Statements .

 

 

7

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

5. Cash, restricted cash and cash equivalents

 

Cash and cash equivalents include the following amounts:

 

    September 30,
2026
    March 31,
2026
 
Unrestricted cash held with chartered banks     21,068,527       7,444,763  
Restricted cash     71,810       47,191  
Total     21,140,337       7,491,954  

 

● unrestricted cash and cash equivalents are held with chartered banks and an investment dealer, and include guaranteed investment certificates and term deposits; and

 

● the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $100,000 (March 31, 2026 – Canadian Dollars $65,000) in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the statements of financial position.

 

6. Equipment

 

    Computer
equipment
 
Cost      
Opening balance, April 1, 2025     15,604  
Additions     228  
At September 30, 2025     15,832  
At March 31, 2026     15,833  
Additions     2,581  
At September 30, 2026     18,414  
         
Accumulated Depreciation        
Opening balance, April 1, 2025     (4,508 )
Charge for the period     (2,634 )
At September 30, 2025     (7,142 )
At March 31, 2026     (9,774 )
Charge for the period     (2,802 )
At September 30, 2026     (12,576 )
         
Carrying Value        
At March 31, 2026     6,059  
At September 30, 2026     5,838  

 

7. Accounts payable and accrued liabilities

 

Accounts payable and accrued liabilities include the following amounts:

 

    September 30,
2026
    March 31,
2026
 
Trade payables     377,906       229,509  
Accrued liabilities     26,958       84,684  
Provisions     64,998       93,521  
Total     469,862       407,714  

 

 

8

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

8. Digital assets

 

During the year ended March 31, 2026, the Company deposited $500,000 onto a financially regulated digital asset custody platform and used these funds to acquire a portfolio of cryptocurrencies. The portfolio is held for investment purposes and is accounted for as an intangible asset using the revaluation model in IAS 38 – Intangible Assets.

 

The following table summarizes the Company’s digital asset holdings as at September 30, 2026 and March 31, 2026:

 

Asset

  Symbol   Quantity     Fair Value
per Unit at
September 30,
2026
    Fair value
September 30,
2026
    Fair value
March 31,
2026
    Revaluation
Increase
 
Bitcoin   BTC     3.25     $ 83,552     $ 271,545     $ 221,762     $ 49,783  
Ethereum   ETH     35     $ 2,684     $ 93,950     $ 73,634     $ 20,316  
Solana   SOL     1,024     $ 118     $ 120,853     $ 85,064     $ 35,789  
Tether   USDT     1,000     $ 1     $ 1,000     $ 1,000       -  
USD Coin   USDC     1,000     $ 1     $ 1,000     $ 1,000       -  
Cash (USD)         7,298     $ 1     $ 7,298     $ 7,298       -  
Total                       $ 495,646     $ 389,758     $ 105,888  

 

During the six months ended September 30, 2026, a revaluation gain of $105,888 (September 30, 2025 - $nil) was recognized in the condensed consolidated interim statements of net loss and comprehensive loss, being a reversal of revaluation decreases previously recognized in profit or loss. Fair values are determined by reference to quoted prices on active cryptocurrency exchanges (Level 1).

 

9. Derivative warrant liabilities

 

The Company has two classes of warrant liabilities outstanding: Public Warrants and Private Warrants. As of September 30, 2026 and March 31, 2026, there were 3,322 warrants issued and outstanding, consisting of 3,169 Public Warrants and 153 Private Warrants. Each warrant is exercisable to purchase one common share at a price of $42,963.28 per share.

 

Public Warrants: The fair value of the Public Warrants is determined based on the observable market price, as they continue to be traded on the Nasdaq under the symbol “PBMWW.” Changes in fair value during the periods ended September 30, 2026 and September 30, 2025, have been recognized in the condensed consolidated interim statements of net loss and comprehensive loss.

 

Private Warrants: The Company utilizes a Black-Scholes options valuation model to value the private warrants at each reporting period, using the following main assumptions:

 

   

Warrant Inputs at

September 30, 2026

   

Warrant Inputs at

March 31,
2026

 
Share price   $ 5.46     $ 2.46  
Expected dividend yield     Nil       Nil  
Exercise price   $ 42,963.28     $ 42,963.28  
Risk-free interest rate     4.21 %     4.21 %
Expected life     2.32       3.00  
Expected volatility     59.98 %     59.98 %
Expiry date     January 25, 2029       January 25, 2029  

 

At September 30, 2026 the fair value of the Public and Private Warrants was $248,640 (March 31, 2026 - $215,476) and $nil (March 31, 2026 - $nil), respectively. A fair value loss of $33,164 (September 30, 2025 – $98,272 loss) was recognized on the condensed consolidated interim statements of loss and comprehensive loss.

 

 

9

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

The expected volatility was based on implied volatility of the Public Warrants.

 

As at September 30, 2026, the derivative warrant liability was reconciled as follows:

 

Derivative warrant liability – Public and Private Warrants

     
    Number     Amount ($)  
Opening balance April 1, 2025     3,322       200,096  
Fair value loss     -       98,272  
Balance as at September 30, 2025     3,322       298,368  
Opening balance April 1, 2026     3,322       215,476  
Fair value loss     -       33,164  
Balance as at September 30, 2026     3,322       248,640  

 

Warrant transactions and the number of warrants outstanding are summarized as follows:

 

    Public Warrants     Private Warrants  
    Number of
Warrants
    Weighted
Average
Exercise
Price
    Number of
Warrants
    Weighted
Average
Exercise
Price
 
Balance, April 1, 2025     3,169     $ 42,963.28       153     $ 42,963.28  
Balance, September 30, 2025 and March 31, 2026     3,169     $ 42,963.28       153     $ 42,963.28  
Balance, September 30, 2026     3,169     $ 42,963.28       153     $ 42,963.28  

 

The following warrants were outstanding and exercisable at September 30, 2026:

 

Issue Date   Expiry Date   Exercise Price     Number of Warrants
Outstanding
    Number of  Warrants
Exercisable
 
January 25, 2024   January 25, 2029   $ 42,963.28       3,322       3,322  

 

10. Loan receivable

 

On February 9, 2026, the Company advanced a loan of $251,110 to Curiosum Ltd. (the “Loan”) in connection with the settlement agreement with KAOS Capital Ltd. The Loan bore interest at RBC Prime Rate + 1% per annum and had a three-month term. As at March 31, 2026, the carrying amount of the Loan, including accrued interest of $1,875, was $252,985.

 

On May 19, 2026, the Loan was repaid in full together with accrued interest of $3,337. Interest income of $1,462 was recognized on the Loan during the six months ended September 30, 2026. As at September 30, 2026 the balance of the loan receivable was $nil.

 

 

10

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

11. ELOC

 

On August 28, 2024, the Company entered into a $25 million equity line of credit (ELOC) agreement with White Lion Capital, LLC, subsequently amended to $100 million, which was declared effective by the U.S. Securities and Exchange Commission (SEC). This agreement allows the Company to sell up to $100 million in shares up until December 31, 2027, subject to specific conditions outlined in the Purchase Agreement.

 

During the six months ended September 30, 2026 the Company issued 1,519,383 (September 30, 2025 - 205,432) common shares under the ELOC for total consideration of $16,931,511 (September 30, 2025 - $7,349,396). Share issuance costs of $151,064 (September 30, 2025 - $293,975) consisted entirely of cash settled share issuance costs.

 

12. Share capital

 

a) Authorized

 

The Company is authorized to issue an unlimited number of Common Shares, each without par value.

 

b) Issued and outstanding

 

On November 26, 2024, the Company consolidated its common shares on the basis of 75:1.

 

On May 5, 2025, the Company consolidated its common shares and warrants on the basis of 7.97:1.

 

On February 2, 2026, the Company consolidated its common shares and warrants on the basis of 6.25:1.

 

All common shares, warrants and value per share amounts have been updated to reflect the share consolidations.

 

As at September 30, 2026, there were 3,816,548 (September 30, 2025 – 299,528) issued and outstanding Common Shares.

 

Common shares   Note     2026     2025  
          Number     Amount ($)     Number     Amount ($)  
Opening balance April 1             2,293,277       78,747,983       90,883       61,752,305  
Shares issued for ELOC     11       1,519,383       16,931,511       205,432       7,349,396  
Shares issued to third party advisors             -       -       2,439       60,000  
Shares issued on RSU exercise             3,888       76,584       774       16,884  
Share issuance costs     11       -       (151,064 )     -       (293,975 )
Balance as at September 30             3,816,548       95,605,014       299,528       68,884,610  

 

Common shares

 

Issuance of shares to third party advisors

 

No common shares were issued to third party advisors during the six months ended September 30, 2026. In May 2025, the Company issued 2,439 common shares to various third party advisors in exchange for professional services.

 

 

11

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

c) Warrant Reserve

 

As at September 30, 2026, there were 41,656 (March 31, 2026 – 41,790) issued and outstanding Warrants. On August 20, 2026, 134 warrants exercisable at $1,867.97 per share expired unexercised.

 

The following warrants were outstanding and exercisable at September 30, 2026:

 

Issue Date   Expiry Date   Exercise
Price
    Number of
Warrants
Outstanding
    Number of
Warrants
Exercisable
 
December 24, 2024   December 24, 2029   $ 99.63       20,075       20,075  
December 24, 2024   December 24, 2026   $ 99.63       20,075       20,075  
December 24, 2024   December 24, 2029   $ 124.53       1,506       1,506  

 

d) Restricted Stock Units (RSUs)

 

RSUs   2026     2025  
    Number  
Opening balance April 1     9,636       -  
RSU’s granted     141,552       2,033  
Exercised     (3,888 )     (774 )
Cancelled     (1,482 )     -  
Balance as at September 30,     145,818       1,259  

 

On June 1, 2026, the Company issued 141,552 RSUs to directors, consultants and employees which are exercisable into common shares of the Company at no additional cost and are to vest as follows:

 

● 47,184 exercisable on December 1, 2026

 

● 47,184 exercisable on June 1, 2027

 

● 47,184 exercisable on December 1, 2027

 

The fair value of the RSUs was determined to be $593,103 based on the fair value of the Company’s common shares of $4.19 on the date of the grant. Upon exercise, the Company shall settle RSUs by way of common shares, with one (1) common share issued for every one (1) RSU exercised.

 

During the six months ended September 30, 2026, 3,888 RSUs were exercised into common shares and 1,482 RSUs were cancelled following the resignation of a consultant. Details of the RSUs granted on April 17, 2025 and October 1, 2025 are disclosed in the Company’s audited consolidated financial statements for the year ended March 31, 2026.

 

13. Investment in Associate – Psyence Labs Ltd.

 

Psyence Labs Ltd. (“PsyLabs”) is a private company headquartered in the British Virgin Islands focused on the production of psychedelic active pharmaceutical ingredients and extracts. On February 25, 2026, the Company’s ownership interest in PsyLabs increased from 16.46% to 27.93% and the Company obtained significant influence over PsyLabs. From that date the investment has been accounted for as an investment in associate using the equity method in accordance with IAS 28 – Investments in Associates and Joint Ventures. Prior to that date the investment was classified as a financial asset at FVTPL, and an unrealized fair value gain of $427,000 was recognized on the investment during the six months ended September 30, 2025.

 

During August 2026, the Company acquired 242 PsyLabs shares from existing PsyLabs shareholders at $2,422 per share for total cash consideration of $586,124.

 

 

12

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

On September 9, 2026, PsyLabs issued a pre-emption notice and backstop subscription commitment to the Company in respect of a new issue of up to 2,138 PsyLabs shares at $2,564 per share, based on an equity valuation of $54,000,000. On September 16, 2026, the Company subscribed for 936 new PsyLabs shares for total consideration of $2,399,904. Under the backstop commitment, the Company agreed to subscribe for any shares not taken up by other PsyLabs shareholders, up to a maximum aggregate subscription amount of $2,600,000, in two milestone-based tranches. The remaining backstop commitment was taken up in full on October 16, 2026 (Note 19).

 

As at September 30, 2026, the Company held 7,078 PsyLabs shares, representing approximately 31.91% of PsyLabs’ issued and outstanding shares.

 

The carrying amount of the investment in associate is reconciled as follows:

 

Investment in Associate      
Carrying amount at March 31, 2026     8,060,928  
Shares acquired from existing shareholders     586,124  
Subscription for new shares     2,399,904  
Share of associate net loss     (306,523 )
Carrying amount at September 30, 2026     10,740,433  

 

During the three and six months ended September 30, 2026, the Company recognized its share of PsyLabs’ net loss of $171,261 and $306,523, respectively, which reduced the carrying amount of the investment.

 

14. Capital management

 

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.

 

The Company manages its capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents on hand.

 

To facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

 

Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company’s approach to capital management during the period.

 

 

13

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

15. Transactions with related parties

 

All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the periods ended September 30, 2026 and September 30, 2025:

 

Compensation to key management personnel

 

Key management personnel are those people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company’s executive officers and Board of Directors.

 

Key Management Personnel   September 30,
2026
    September 30,
2025
 
Short term benefits     459,502       469,346  
Share based compensation     202,683       22,996  
Total     662,185       492,342  

 

Short term benefits consist of consulting fees, director’s fees, payroll and other benefits paid to key management personnel. This is included in the professional and consulting fees and general and administrative line items in the condensed consolidated interim statements of net loss and comprehensive loss.

 

Share-based compensation relates to RSUs granted to key management personnel.

 

During the six months ended September 30, 2026, the Company acquired 130 PsyLabs shares from certain existing PsyLabs shareholders that are related parties of the Company, at $2,422 per share (Note 13).

 

On September 25, 2026, TIRC and Psyence Labs Ltd. entered into a binding term sheet under which PsyLabs will grant TIRC an exclusive licence in the United States to PsyLabs’ know-how and related intellectual property for its cGMP ibogaine HCl, appoint TIRC as its exclusive supplier and wholesale distributor of the product in the United States, and receive development milestone payments totaling up to approximately US$1.3 million for the first drug candidate, an annual exclusivity fee commencing on the first anniversary of the first FDA approval and creditable against royalties, and a low single-digit percentage royalty on net sales of each drug candidate, together with a margin-sharing arrangement on any resale of product by TIRC. As of the date of these financial statements, the Company has not met any of the milestones noted above.

 

16. Share based compensation

 

During the period ended September 30, 2026, $287,737 (September 30, 2025 - $26,329) was recognised for options and restricted stock units (“RSU’s”) granted by the Company under professional and consulting fees expenses and general and administrative expenses on the condensed consolidated interim statements of net loss and comprehensive loss.

 

 

14

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

17. Financial instruments and financial risk management

 

a) Financial instrument classification and fair value measurement

 

Financial instruments that are recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.

 

The fair value of hierarchy has the following levels:

 

● Level 1 – quoted prices in active markets for identical financial instruments.

 

● Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.

 

● Level 3 – valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The table below presents the carrying value of the Company’s financial instruments:

 

    Level 1     Level 2     Level 3     Total  
Digital assets     495,646       -       -       495,646  
Derivative warrant liabilities – public warrants     248,640       -       -       248,640  
Balance, September 30, 2026     744,286       -       -       744,286  
Digital assets     389,758       -       -       389,758  
Derivative warrant liabilities – public warrants     215,476       -       -       215,476  
Balance, March 31, 2026     605,234       -       -       605,234  

 

There were no transfers in and out of level 3 during the period.

 

b) Risk management

 

In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company’s Board of Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework.

 

Credit risk

 

Credit risk arises from cash, restricted cash and cash equivalents held with banks and investment dealers. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions.

 

 

15

 

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

 

 

Liquidity risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

 

The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company’s main source of funding has been through equity investments and from government rebates in respect of research and development expenditure. The Company’s access to financing is uncertain. There can be no assurance of continued access to significant equity or debt funding.

 

The following table set forth the maturity of the contractual obligations as at September 30, 2026 and after

 

    Carrying
Amount
    Contractual
Cash Flows
    Less than 1
year
    Between 1
and 3 years
 
Accounts payable & accrued liabilities     469,862       469,862       469,862       -  
Total contractual obligations     469,862       469,862       469,862           -  

 

Interest rate risk

 

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s cash equivalents include fixed-rate guaranteed investment certificates and term deposits, and variable-rate deposit accounts. Assuming balances at September 30, 2026 are maintained and fixed-rate deposits are reinvested on maturity, a 1% change in interest rates would change interest income over the following twelve months by $99,522. The Company has no interest-bearing liabilities.

 

Foreign exchange risk

 

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

 

As at September 30, 2026, a 10% fluctuation in foreign exchange rates would result in a $70,088 impact to net loss and comprehensive loss.

 

18. Other income

 

Other income for the six months ended September 30, 2026 of $424,695 (September 30, 2025 - $2,533) comprises insurance recoveries received from the Company’s insurer in respect of legal fees incurred in connection with the shareholder dispute with KAOS Capital Ltd., which was settled in February 2026.

 

19. Subsequent Events

 

Subsequent to period end, the Company received gross proceeds of $8,374 for the issuance of 1,580 common shares in relation to the ELOC.

 

On October 12, 2026, directors, consultants and employees of the Company exercised 2,590 RSUs into common shares of the Company.

 

On October 1, 2026, the Company completed a share-for-share swap with PsyLabs pursuant to the Share-for-Share Swap and Nomination Agreement dated September 21, 2026. The Company issued 1,497,500 common shares to PsyLabs, at a deemed issue price of $6.00 per share (aggregate agreed value of $8,985,000), and in exchange PsyLabs issued 3,473 new PsyLabs ordinary shares to Psyence Biomed II Corp., as the Company’s nominee, based on an agreed PsyLabs equity valuation of $60,000,000.

 

On October 16, 2026, the Company completed the second part of the PsyLabs equity raise, subscribing for a further 1,014 PsyLabs shares at $2,564 per share for total cash consideration of $2,599,896 under its backstop subscription commitment. Together with the 936 PsyLabs shares subscribed for in September 2026, the Company subscribed for 1,950 PsyLabs shares for total cash consideration of $4,999,800, representing approximately $5.0 million of the $5.5 million PsyLabs equity raise. Following this subscription and share-for-share swap, the Company holds 11,565 PsyLabs shares, representing approximately 43.37% of PsyLabs’ issued and outstanding shares.

 

On November 10, 2026, Psyence Australia Pty Ltd received a research and development tax incentive rebate of AUD $1,034,681 ($710,363) from the Australian Taxation Office under the Australian Federal Government’s Research and Development Tax Incentive Program, in respect of eligible research and development expenditure incurred in Australia. In accordance with the Company’s accounting policy for government grants, the rebate will be recognized as other income in the period in which it was received.

 

 

16

 

Exhibit 99.2

 

 

 

Psyence Biomedical Ltd.

 

Management Discussion and Analysis (MD&A)

 

For the three and six months ended September 30, 2026 and 2025

 

Expressed in United States Dollars

 

(USD $)

 

 

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

Operating and Financial Review for the three and six-month periods ended September 30, 2026 and 2025 

 

The following discussion of the results of our operations and our financial condition should be read in conjunction with the unaudited condensed consolidated financial statements included as Exhibit 99.1 to this report. This discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. Actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth in “Item 3. Key Information–D. Risk Factors” set forth in our Annual Report on Form 20-F for the year ended March 31, 2026 filed with the SEC on June 22, 2026.

 

This MD&A is dated November 19, 2026. Unless otherwise stated, all amounts are expressed in US dollars and are presented in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, including IAS 34 Interim Financial Reporting. All share and per share amounts reflect the share consolidations completed on November 26, 2024 (75:1), May 5, 2025 (7.97:1) and February 2, 2026 (6.25:1), including for comparative periods.

 

Business overview

 

Psyence Biomedical Ltd. (NASDAQ:PBM) (the “Company” or “PBM”), is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in Neuroplastogens-based therapeutics, the manufacture of pharmaceutical-grade drug candidates and conducting clinical trials. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived Neuroplastogens treatments across a range of mental health disorders

 

We strive to set the global standard for excellence and consistency in drug development using nature-based psilocybin and ibogaine products. PBM’s priority is developing pharmaceutical grade psilocybin and ibogaine to help heal psychological trauma and the diagnosable disorders that can result therefrom, including adjustment disorder (“AjD”), alcohol use disorder (“AUD”), other substance use disorders, anxiety, depression, post-traumatic stress disorder (“PTSD”), and grief and bereavement, especially in the context of palliative care. Our focus includes therapeutic protocols for medical and scientific research including observational studies.

 

Our lead product candidate is NPX-5, a capsule containing 25mg naturally sourced psilocybin and which is being used in our Phase IIb double-blind, randomized, placebo (1mg low dose) controlled clinical trial to assess the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of AjD due to a cancer diagnosis (the “Phase IIb Study”).

 

We have contracted Southern Star Research, a contract research organisation (“CRO”) in Australia that specializes in the study of psychedelics, to conduct the Phase IIb Study. Outsourcing the Phase IIb Study to a CRO assists the Company in operating in a more capital efficient manner without the overhead of handling in-house. The study has received approval from the Australian Human Research Ethics Committees (HREC), numerous sites are currently active, and multiple patients have been dosed.

 

On September 8, 2026, the Company incorporated Texas Ibogaine Research Corporation (“TIRC”), a wholly owned subsidiary of Psyence Biomed II Corp., to advance the Company’s planned expansion into the treatment of opioid use disorder (“OUD”) using ibogaine in the United States. On September 25, 2026, TIRC and Psyence Labs Ltd. (“PsyLabs”) entered into a binding term sheet under which PsyLabs will grant TIRC an exclusive licence in the United States to PsyLabs’ know-how and related intellectual property for its cGMP ibogaine HCl, appoint TIRC as its exclusive supplier and wholesale distributor of the product in the United States, and receive development milestone payments totaling up to approximately US$1.3 million for the first drug candidate, an annual exclusivity fee commencing on the first anniversary of the first FDA approval and creditable against royalties, and a low single-digit percentage royalty on net sales of each drug candidate, together with a margin-sharing arrangement on any resale of product by TIRC.

 

The Company holds a significant interest in PsyLabs, a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. Psylabs is accounted for as an associate using the equity method. As at September 30, 2026 the Company held approximately 31.9% of PsyLabs, increasing to approximately 43.4% following the transactions completed in October 2026 described under “Subsequent events”.

 

2

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

Operating results

 

Our key financial results for the three and six months ended September 30, 2026 and 2025 are summarized below:

 

USD $  Three months ended
Sep 30,
2026
   Three months ended
Sep 30,
2025
   Six months ended
Sep 30,
2026
   Six months ended
Sep 30,
2025
 
Sales and marketing   (105,506)   (48,670)   (119,646)   (154,976)
Research and development   (527,967)   (357,444)   (890,254)   (672,364)
General and administrative   (173,282)   (217,225)   (320,000)   (367,070)
Professional and consulting fees   (782,312)   (881,638)   (1,151,393)   (1,223,637)
Loss before other items   (1,589,067)   (1,504,977)   (2,481,293)   (2,418,047)
Other income   424,695    -    424,695    2,533 
Interest income   224,287    72,815    362,187    103,341 
Fair value gain/(loss) on warrant liability   39,072    (58,016)   (33,164)   (98,272)
Fair value gain on digital assets   165,868    -    105,888    - 
Fair value gain on investment in Psyence Labs Ltd   -    740,750    -    427,000 
Share of losses from Associate   (171,261)   -    (306,523)   - 
Depreciation, interest expense and foreign exchange   (6,499)   (3,826)   (8,848)   (9,287)
Net loss for the period   (912,905)   (753,254)   (1,937,058)   (1,992,732)
Loss per share – basic and diluted   (0.24)   (3.18)   (0.53)   (11.76)

 

USD $  September 30,
2026
   March 31,
2026
 
Cash and cash equivalents, including restricted cash   21,140,337    7,491,954 
Working capital   20,837,679    8,487,385 
Investment in Associate   10,740,433    8,060,928 
Total assets   32,798,098    17,567,320 
Total liabilities   718,502    623,190 
Total shareholders’ equity   32,079,596    16,944,130 

 

Comparative loss per share has been restated to reflect the 6.25:1 share consolidation completed on February 2, 2026.

 

Sales and marketing costs

 

For the six months ended September 30, 2026, we incurred sales and marketing costs of $119,646 (September 30, 2025: $154,976), consisting primarily of investor relations activities, travel, content creation, promotional materials and website-related costs. For the three months ended September 30, 2026, sales and marketing costs were $105,506 (September 30, 2025: $48,670).

 

The decrease for the six-month period reflects the Company’s reduced spending on investor relations and promotional activities. The increase for the three months ended September 30, 2026 reflects attendance at ARPA-H conferences in the United States and visits to a contract development and manufacturing organization (“CDMO”) in Texas in connection with the Company’s planned expansion into OUD using ibogaine through TIRC.

 

Research and development

 

For the six months ended September 30, 2026, we incurred research and development costs of $890,254 (September 30, 2025: $672,364), of which $878,347 related to the Phase IIb Study conducted in Australia, $6,952 to the Company’s ibogaine program through TIRC and $4,956 to other research activities. For the three months ended September 30, 2026, research and development costs were $527,967 (September 30, 2025: $357,444) which was all related to the Phase IIb Study conducted in Australia.

 

The increase reflects the continued progression of the Phase IIb Study under Southern Star Research, including patient recruitment and dosing, site management, monitoring and ongoing trial management across the activated trial sites. The research and development tax incentive rebate was received after the period end. The Company expects research and development expenditure to continue to increase as the Phase IIb Study progresses and as the ibogaine program is developed through TIRC.

 

3

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

General and administration costs

 

For the six months ended September 30, 2026, we incurred general and administrative costs of $320,000 (September 30, 2025: $367,070), which consisted of filing and listing fees, bank fees, directors’ and officers’ insurance, salaries and wages and operational costs. For the three months ended September 30, 2026, general and administrative costs were $173,282 (September 30, 2025: $217,225).

 

The decrease reflects the Company’s continued focus on cost discipline across corporate overhead and the normalization of public company compliance costs.

 

Professional and consulting fees

 

For the six months ended September 30, 2026, professional and consulting fees totalled $1,151,393 (September 30, 2025: $1,223,637). For the three months ended September 30, 2026, professional and consulting fees were $782,312 (September 30, 2025: $881,638).

 

This consisted of $954,974 (September 30, 2025: $420,298) paid to consultants, directors and key management personnel for business strategy, financial and administrative services, including non-cash share-based compensation of $269,043 on restricted stock units (“RSUs”), legal fees of $104,481 (September 30, 2025: $734,977) and $91,938 (September 30, 2025: $68,362) for audit and accounting fees.

 

The decrease in legal fees reflects the legal costs incurred on a higher volume of corporate transactions in the prior period. The increase in consulting fees reflects share-based compensation on the RSUs granted on October 1, 2025 and June 1, 2026, performance-related payments to consultants and expanded advisory support for the Company’s corporate and strategic initiatives.

 

Other income, gains and losses

 

Other income of $424,695 for the six months ended September 30, 2026 (September 30, 2025: $2,533) comprises insurance recoveries received from the Company’s insurer in respect of legal fees incurred in connection with the shareholder dispute with KAOS Capital Ltd., which was settled in February 2026.

 

Interest income increased to $362,187 (September 30, 2025: $103,341), driven by higher cash balances available for investment in guaranteed investment certificates and term deposits.

 

The Company recognized a fair value loss of $33,164 (September 30, 2025: loss of $98,272) on its derivative warrant liabilities, reflecting the movement in the quoted price of the public warrants, and a revaluation gain of $105,888 (September 30, 2025: $nil) on its digital asset portfolio, reflecting higher cryptocurrency prices at September 30, 2026.

 

Investment in Psyence Labs Ltd.

 

PsyLabs has been accounted for as an associate using the equity method since February 25, 2026. For the three and six months ended September 30, 2026, the Company recognized its share of PsyLabs’ net loss of $171,261 and $306,523, respectively. In the comparative period the investment was measured at fair value through profit or loss, and an unrealized fair value gain of $427,000 was recognized for the six months ended September 30, 2025.

 

During the six months ended September 30, 2026, the Company invested a further $2,986,028 in cash in PsyLabs, comprising 242 shares acquired from existing PsyLabs shareholders at $2,422 per share for $586,124 and 936 new shares subscribed at $2,564 per share for $2,399,904 in the first part of PsyLabs’ $5.5 million equity raise. As at September 30, 2026, the Company held 7,078 PsyLabs shares, representing approximately 31.9% of PsyLabs’ issued and outstanding shares, and the carrying amount of the investment was $10,740,433 (March 31, 2026: $8,060,928).

 

4

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

Update to Palliative Care Clinical Trial

 

The 87 - patient Phase IIb Study being conducted by the CRO, Southern Star Research, in Australia is the one that was discussed with the FDA at the pre-IND stage. The study has received ethics (HREC) approval, and multiple patients have been enrolled and dosed.

 

Liquidity and capital resources

 

Since incorporation, our operations have been financed primarily through equity, including investment by our shareholders, a private placement and an equity line of credit (“ELOC”), together with a convertible debt note and research and development tax incentive rebates from the Australian Government. Our main use for liquidity is funding scientific research, clinical studies, salaries and professional and consulting fees. Our ability to fund operations and to make planned cash flows are subject to prevailing economic conditions, regulatory and financial, business, and other factors, some of which are beyond our control.

 

As of September 30, 2026, we had cash and cash equivalents, including restricted cash, of $21,140,337 (March 31, 2026: $7,491,954) and working capital of $20,837,679 (March 31, 2026: $8,487,385). Cash and cash equivalents include guaranteed investment certificates and term deposits held with a chartered bank and an investment dealer.

 

For the six months ended September 30, 2026, cash used in operating activities was $394,565 (September 30, 2025: $2,029,147). Operating cash outflows were reduced by the realization of prepaid amounts of $897,751, including funds held in trust with attorneys at March 31, 2026, and by insurance recoveries of $424,695. Cash used in investing activities was $2,762,118 (September 30, 2025: $4,011,455), primarily comprising the $2,986,028 investment in PsyLabs, partly offset by the repayment of the $251,110 loan receivable. Cash provided by financing activities was $16,780,447 (September 30, 2025: $7,055,421), being the net proceeds from the issuance of 1,519,383 common shares under the ELOC.

 

The ELOC with White Lion Capital, LLC, as amended, allows the Company to sell up to $100 million of its common shares until December 31, 2027, subject to the conditions set out in the purchase agreement. As at the date of this MD&A, $61,836,722 remains available under the ELOC.

 

The Company’s material cash requirements as at September 30, 2026 comprise its commitments for the Phase IIb Study, the development of its ibogaine program, and its backstop subscription commitment to PsyLabs of up to $2,600,000, which was satisfied on October 16, 2026 with a payment of $2,599,896. The Company expects to fund these requirements with available cash and cash equivalents, and therefore, is subject to risks including, but not limited to, an inability to raise additional funds through the issuance of equity, debt instruments or similar means of financing to support the Company’s continued development, including operating requirements, and to meet its liabilities and commitments as they become due.

 

The Company has experienced cash outflows from operations since incorporation and by nature of its business, will require ongoing financing to continue its research and development operations. The Company’s ability to access both public and private capital is dependent upon, among other things, general and sectoral market conditions and the capital markets generally, market perceptions about the Company and its business operations, and the trading prices of the Company’s securities from time to time. There can be no assurance that additional funds can be raised upon terms acceptable to the Company, or at all, as funding for early-stage companies remain challenging generally.

 

The Company’s primary capital needs are funds to advance its research and development activities and for working capital purposes. These activities include staffing, pre-clinical studies, clinical trials, professional and consulting fees and general and administrative costs. There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favourable for the Company as those previously obtained, or at all.

 

Research and development, patents and licenses

 

Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.

 

5

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.

 

Critical Accounting Estimates

 

The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical accounting policies as these require a high level of subjectivity and judgement and could have a material impact on PBM’s financial statements.

 

Investment in associate

 

Management applied judgment in determining that the Company has significant influence over PsyLabs and accounts for its interest using the equity method. The Company’s share of PsyLabs’ results is based on PsyLabs’ management accounts for the period. At each reporting date management assesses whether there is objective evidence that the investment is impaired, which requires judgment regarding PsyLabs’ financial performance, funding and development progress.

 

Digital assets

 

Digital assets are accounted for as intangible assets using the revaluation model under IAS 38, with fair values determined by reference to quoted prices on active exchanges. Judgment is required in the classification of digital assets and in determining whether revaluation movements are recognized in profit or loss or other comprehensive income.

 

Share-based compensation 

 

The fair value of RSUs is measured by reference to the market price of the Company’s common shares on the grant date, and the expense is recognized over the vesting period based on management’s estimate of the number of RSUs expected to vest.

 

Quantitative and Qualitative Disclosures About Financial Instruments and Financial Risk Management

 

In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management, as well as monitoring. Our Board has overall responsibility for the establishment and oversight of the Company’s risk management framework.

 

Credit risk

 

Credit risk arises from cash, restricted cash and cash equivalents held with banks and an investment dealer, and from digital assets held with a regulated digital asset custodian. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions. The Company also assesses the credit quality of counterparties, taking into account their financial position, past experience and other factors.

 

6

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

Liquidity risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

 

The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. The Company’s access to financing is always uncertain and there can be no assurance of continued access to significant equity or debt funding on terms satisfactory to the Company, or at all.

 

Foreign exchange risk

 

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

 

The Company operates internationally and is exposed to foreign exchange risk from the Canadian Dollar and the Australian Dollar. Foreign exchange risk arises from transactions as well as recognized financial assets and liabilities denominated in foreign currencies.

 

A 10% adverse change in exchange rate would have resulted in a loss of $70,088 as of September 30, 2026.

 

Management mitigates the risk of adverse exchange rate movements by holding funds in US dollars.

 

Interest rate risk

 

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s cash equivalents include fixed-rate guaranteed investment certificates and term deposits, and variable-rate deposit accounts. Assuming balances at September 30, 2026 are maintained and fixed-rate deposits are reinvested on maturity, a 1% change in interest rates would change interest income over the following twelve months by $99,522. The Company has no interest-bearing liabilities.

 

Digital asset price risk

 

The Company is exposed to price risk on its portfolio of digital assets. A 10% decrease in the prices of the portfolio of digital assets at September 30, 2026 would have decreased the carrying amount of digital assets, and increased net loss, by approximately $48,635.

 

Capital Management

 

The Company’s objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, issue debt, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.

 

Management reviews its capital management approach on an ongoing basis. The Company considers its shareholders’ equity balance as capital.

 

Off-Balance Sheet Arrangements

 

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2026. We do not participate in transactions that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities or guaranteed any debt or commitments of other entities.

 

Contractual Obligations

 

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.

 

As at September 30, 2026, the Company’s contractual obligations comprised accounts payable and accrued liabilities of $469,862, all due within one year, and its backstop subscription commitment to PsyLabs of up to $2,600,000, which was satisfied on October 16, 2026.

 

7

 

Psyence Biomedical Ltd.

Management Discussion and Analysis

 

 

Transactions with related parties

 

Compensation to key management personnel for the six months ended September 30, 2026 was $662,185 (September 30, 2025: $492,342), comprising short-term benefits of $459,502 (September 30, 2025: $469,346) and share-based compensation of $202,683 (September 30, 2025: $22,996). During the period the Company also acquired 130 PsyLabs shares from certain existing PsyLabs shareholders that are related parties of the Company, at $2,422 per share. Refer to Note 15 of the unaudited condensed consolidated interim financial statements.

 

Outstanding share data

 

As at September 30, 2026, the Company had 3,816,548 common shares, 41,656 equity-classified warrants, 3,322 derivative warrants and 145,818 RSUs outstanding. As at the date of this MD&A, the Company had 5,318,218 common shares, 41,656 equity-classified warrants, 3,322 derivative warrants and 143,228 RSUs outstanding.

 

Subsequent events

 

On October 1, 2026, the Company completed a share-for-share swap with PsyLabs, issuing 1,497,500 common shares to PsyLabs at a deemed issue price of $6.00 per share in exchange for 3,473 new PsyLabs shares issued to Psyence Biomed II Corp. The fair value of the common shares issued, based on the closing share price of $5.48 on October 1, 2026, was $8,206,300.

 

On October 16, 2026, the Company subscribed for a further 1,014 PsyLabs shares at $2,564 per share for $2,599,896, completing its participation of approximately $5.0 million in PsyLabs’ $5.5 million equity raise. Following these transactions, the Company holds 11,565 PsyLabs shares, representing approximately 43.4% of PsyLabs’ issued and outstanding shares.

 

On November 10, 2026, Psyence Australia Pty Ltd received a research and development tax incentive rebate of AUD $1,034,681 ($710,363) from the Australian Taxation Office under the Australian Federal Government’s Research and Development Tax Incentive Program, in respect of eligible research and development expenditure incurred in Australia. In accordance with the Company’s accounting policy for government grants, the rebate will be recognized as other income in the period in which it was received.

 

Subsequent to period end, the Company received gross proceeds of $8,374 for the issuance of 1,580 common shares under the ELOC, and on October 12, 2026 directors, consultants and employees of the Company exercised 2,590 RSUs into common shares.

 

8

Filing Exhibits & Attachments

7 documents

Keep reading